The upgrade in the price target by a reputable analyst like Tessa Romero from JP Morgan is a strong positive signal for Neumora Therapeutics. It suggests confidence in the company's future performance and growth potential, likely leading to increased investor interest and potentially a rise in stock price in the short term.